FDA’s Office of Hematology and Oncology Products Reorganizes
Earlier this month, the U.S. Food and Drug Administration (FDA) announced that the Office of Hematology and Oncology Products...
Category: Policy
Earlier this month, the U.S. Food and Drug Administration (FDA) announced that the Office of Hematology and Oncology Products...
On Wednesday, the U.S. Food and Drug Administration (FDA) expanded the use of the molecularly targeted therapeutic niraparib (Zejula)...
Breast cancer can be a scary diagnosis. Even though mortality rates have declined in recent years in the United...
The use of immunotherapy in the treatment of cancer has dramatically increased in the five years since the U.S....
In the effort to include more diverse patient populations in clinical trials, good intentions can easily go awry. Panelists...
Policy plays a critical role in the fight against cancer, influencing the funding of cancer research and driving the...
Last week, the U.S. Food and Drug Administration (FDA) approved the second of a new wave of molecularly targeted...
During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib...
Building on advances in technology and analytical tools, real-world data (RWD) sources have attracted increasing interest as means to...
Every two minutes, a woman somewhere in the world dies of cervical cancer. That harrowing statistic, shared by Anna R....